Detalhe da pesquisa
1.
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Blood
; 141(16): 1971-1981, 2023 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626583
2.
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Lancet Oncol
; 25(1): 117-125, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38092009
3.
Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma.
Br J Haematol
; 204(5): 1771-1779, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447995
4.
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.
Blood
; 139(21): 3148-3158, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35303070
5.
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235512
6.
Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus-associated mantle cell lymphoma.
Hematol Oncol
; 42(3): e3268, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38676394
7.
Sublethal effects of chlorantraniliprole on immunity in Spodoptera frugiperda (Smith) (Lepidoptera: Noctuidae): Promote encapsulation by upregulating a heat shock protein 70 family gene SfHSP68.1.
Pestic Biochem Physiol
; 201: 105892, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38685254
8.
Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE.
Int J Cancer
; 153(5): 1016-1025, 2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37204683
9.
OX40 shapes an inflamed tumor immune microenvironment and predicts response to immunochemotherapy in diffuse large B-cell lymphoma.
Clin Immunol
; 251: 109637, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37150239
10.
Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma.
Br J Haematol
; 202(6): 1151-1164, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37455019
11.
Efficacy and safety of geptanolimab (GB226) for relapsed/refractory primary mediastinal large B-cell lymphoma: an open-label phase II study (Gxplore-003).
Cancer Immunol Immunother
; 72(9): 2991-3002, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37289256
12.
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
Invest New Drugs
; 41(4): 606-616, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37420136
13.
Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database.
Haematologica
; 108(9): 2467-2475, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36951150
14.
First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
BMC Cancer
; 23(1): 746, 2023 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37568079
15.
Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis.
Hematol Oncol
; 41(2): 239-247, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-34564882
16.
Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study.
Ann Hematol
; 102(9): 2459-2469, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306711
17.
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
Am J Hematol
; 98(4): 571-579, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36683422
18.
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Am J Hematol
; 98(11): 1742-1750, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37647123
19.
A retrospective analysis of EBV-DNA status with the prognosis of lymphoma.
J Cell Mol Med
; 26(20): 5195-5201, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36065965
20.
A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.
Clin Immunol
; 243: 109105, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36055572